Data from CorEvitas RA registry shows persistence for first-line monotherapy with etanercept, adalimumab and JAKis no different at 12 months. 20-25% switching at 12-months. Clearly more to secondary failure than anti-drug antibodies.
@RheumNow #ACR22
https://t.co/FeP0UAykUg https://t.co/ad9w9lI0Hu
Links:
Outcomes in Patients with Rheumatoid Arthritis Initiating Monotherapy with Etan…
https://tinyurl.com/yu26rfn2
13-11-2022